242 related articles for article (PubMed ID: 24418171)
1. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection.
Larrea E; Echeverria I; Riezu-Boj JI; Aldabe R; Guembe L; Sola I; Civeira MP; Sarobe P; Prieto J
J Hepatol; 2014 Mar; 60(3):482-9. PubMed ID: 24418171
[TBL] [Abstract][Full Text] [Related]
2. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
Underhill-Day N; Heath JK
Cancer Res; 2006 Nov; 66(22):10891-901. PubMed ID: 17108126
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes.
Larrea E; Riezu-Boj JI; Aldabe R; Guembe L; Echeverria I; Balasiddaiah A; Gastaminza P; Civeira MP; Sarobe P; Prieto J
Gut; 2014 Apr; 63(4):665-73. PubMed ID: 23787026
[TBL] [Abstract][Full Text] [Related]
4. Loss of oncostatin M receptor beta in metastatic melanoma cells.
Lacreusette A; Nguyen JM; Pandolfino MC; Khammari A; Dreno B; Jacques Y; Godard A; Blanchard F
Oncogene; 2007 Feb; 26(6):881-92. PubMed ID: 16909117
[TBL] [Abstract][Full Text] [Related]
5. Altered expression and activation of signal transducers and activators of transcription (STATs) in hepatitis C virus infection: in vivo and in vitro studies.
Larrea E; Aldabe R; Molano E; Fernandez-Rodriguez CM; Ametzazurra A; Civeira MP; Prieto J
Gut; 2006 Aug; 55(8):1188-96. PubMed ID: 16120756
[TBL] [Abstract][Full Text] [Related]
6. Oncostatin M enhances the antiviral effects of type I interferon and activates immunostimulatory functions in liver epithelial cells.
Larrea E; Aldabe R; Gonzalez I; Segura V; Sarobe P; Echeverria I; Prieto J
J Virol; 2009 Apr; 83(7):3298-311. PubMed ID: 19158240
[TBL] [Abstract][Full Text] [Related]
7. CD40 inhibits replication of hepatitis C virus in primary human hepatocytes by c-Jun N terminal kinase activation independent from the interferon pathway.
Rau SJ; Hildt E; Himmelsbach K; Thimme R; Wakita T; Blum HE; Fischer R
Hepatology; 2013 Jan; 57(1):23-36. PubMed ID: 22814930
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of a splice variant of oncostatin M receptor beta in human esophageal squamous carcinoma.
Kausar T; Sharma R; Hasan MR; Saraya A; Chattopadhyay TK; Gupta SD; Ralhan R
Cell Oncol (Dordr); 2011 Jun; 34(3):177-87. PubMed ID: 21394648
[TBL] [Abstract][Full Text] [Related]
9. Oncostatin M induces dendritic cell maturation and Th1 polarization.
Jung ID; Noh KT; Lee CM; Chun SH; Jeong SK; Park JW; Park WS; Kim HW; Yun CH; Shin YK; Park YM
Biochem Biophys Res Commun; 2010 Apr; 394(2):272-8. PubMed ID: 20206608
[TBL] [Abstract][Full Text] [Related]
10. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
[TBL] [Abstract][Full Text] [Related]
11. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
[TBL] [Abstract][Full Text] [Related]
12. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
[TBL] [Abstract][Full Text] [Related]
13. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection.
Riezu-Boj JI; Larrea E; Aldabe R; Guembe L; Casares N; Galeano E; Echeverria I; Sarobe P; Herrero I; Sangro B; Prieto J; Lasarte JJ
J Hepatol; 2011 Mar; 54(3):422-31. PubMed ID: 21129807
[TBL] [Abstract][Full Text] [Related]
15. Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells.
MacDonald AJ; Semper AE; Libri NA; Rosenberg WM
Clin Exp Immunol; 2007 Jun; 148(3):494-500. PubMed ID: 17362265
[TBL] [Abstract][Full Text] [Related]
16. The role of the oncostatin M/OSM receptor β axis in activating dermal microvascular endothelial cells in systemic sclerosis.
Marden G; Wan Q; Wilks J; Nevin K; Feeney M; Wisniacki N; Trojanowski M; Bujor A; Stawski L; Trojanowska M
Arthritis Res Ther; 2020 Jul; 22(1):179. PubMed ID: 32736577
[TBL] [Abstract][Full Text] [Related]
17. Decrease and dysfunction of dendritic cells correlate with impaired hepatitis C virus-specific CD4+ T-cell proliferation in patients with hepatitis C virus infection.
Della Bella S; Crosignani A; Riva A; Presicce P; Benetti A; Longhi R; Podda M; Villa ML
Immunology; 2007 Jun; 121(2):283-92. PubMed ID: 17462079
[TBL] [Abstract][Full Text] [Related]
18. The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice.
Adrian-Segarra JM; Sreenivasan K; Gajawada P; Lörchner H; Braun T; Pöling J
J Biol Chem; 2018 Dec; 293(52):20181-20199. PubMed ID: 30373773
[TBL] [Abstract][Full Text] [Related]
19. Oncostatin M-enhanced vascular endothelial growth factor expression in human vascular smooth muscle cells involves PI3K-, p38 MAPK-, Erk1/2- and STAT1/STAT3-dependent pathways and is attenuated by interferon-γ.
Demyanets S; Kaun C; Rychli K; Pfaffenberger S; Kastl SP; Hohensinner PJ; Rega G; Katsaros KM; Afonyushkin T; Bochkov VN; Paireder M; Huk I; Maurer G; Huber K; Wojta J
Basic Res Cardiol; 2011 Mar; 106(2):217-31. PubMed ID: 21174212
[TBL] [Abstract][Full Text] [Related]
20. Oncostatin-M-Reactive Pericytes Aggravate Blood-Brain Barrier Dysfunction by Activating JAK/STAT3 Signaling In Vitro.
Takata F; Dohgu S; Sakaguchi S; Sakai K; Yamanaka G; Iwao T; Matsumoto J; Kimura I; Sezaki Y; Tanaka Y; Yamauchi A; Kataoka Y
Neuroscience; 2019 Dec; 422():12-20. PubMed ID: 31705893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
